Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease

Razak, Albiruni Ryan Abdul; Li, Louise; Bryant, Andrew; Díaz-Padilla, Iván

doi:10.1002/14651858.cd007584.pub2

Cited by 12 publications

(8 citation statements)

References 24 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is known that pathology and FIGO stage are two vital factors that may confer resistance to chemotherapy in non-pregnant ovarian cancer patients. 55,56 This is comparable to the results reported by log-rank test that patients with early stage (I) had a better OS and PFS than advanced stage (II-IV) of ovarian cancer in pregnancy. Worthy of note, several cases with stage I that did not received chemotherapy during pregnancy were not included in this study.…”

Section: Discussionsupporting

confidence: 84%

“…This indicates chemotherapy administration is effective for ovarian cancer patients in the second and third trimesters of pregnancy. It is known that pathology and FIGO stage are two vital factors that may confer resistance to chemotherapy in non‐pregnant ovarian cancer patients 55,56 . This is comparable to the results reported by log‐rank test that patients with early stage (I) had a better OS and PFS than advanced stage (II–IV) of ovarian cancer in pregnancy.…”

Section: Discussionsupporting

confidence: 78%

See 1 more Smart Citation

Chemotherapy for ovarian cancer during pregnancy: A systematic review and meta‐analysis of case reports and series

Jiang

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim: This study aims to investigate the safety and efficacy of chemotherapy in ovarian cancer patients in pregnancy. Methods: In this study, eligible studies were searched on PubMed, Embase, and Cochrane Library databases up to December 31, 2020. Data were calculated and presented by frequency and percentage, mean AE standard deviation (SD), and median (range), respectively. Kaplan-Meier survival analysis was performed to estimate overall survival (OS) and progression-free survival (PFS). Results: Finally, 34 studies including 40 ovarian cancer cases receiving chemotherapy during pregnancy were included. All 40 patients received chemotherapy during pregnancy. During the follow-up, seven of 37 (18.9%) women had a relapse and four of them (4/7, 57.1%) died of recurrence. Survival analysis failed to reach median OS and PFS within the follow-up (range 3-72 months). Better OS and PFS after chemotherapy in pregnancy were obtained in women with early-stage ovarian cancer (I) compared with those with advanced stage (III-IV). Neither OS nor FS differed between women treated with multi-drugs and those with monotherapy. Forty-one newborns were delivered from 40 pregnant women. Thirty-four (34/41, 82.9%) were completely healthy at birth and the end of follow-up (range 0.18-160 months). However, one newborn died 5 days after birth due to multiple congenital malformations, and another one developed Tourette's syndrome, aphasia, Asperger's syndrome as well as speech delay. Conclusions: This meta-analysis first reveals the efficacy and safety of chemotherapy for ovarian cancer during pregnancy, especially for early-stage patients. Cisplatin or carboplatin is suggested to be used as monotherapy to reduce adverse effects.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionsupporting

confidence: 78%

Chemotherapy for ovarian cancer during pregnancy: A systematic review and meta‐analysis of case reports and series

Jiang

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…No clinical study has assessed the efficacy of Etoposide-Platinum (EP) in ovarian GCT [11] , [12] . Based on data extrapolated from the testicular cancer literature, rather than from prospective trials in the malignant OGCT population, the use of EP can be considered in patients who cannot receive bleomycin.…”

Section: Discussionmentioning

confidence: 99%

Death by bleomycin pulmonary toxicity in ovarian dysgerminoma with pathologic complete response to chemotherapy. A case report

Rodríguez

Morales

Casero

2016

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

With cisplatin-based chemotherapy, most patients with ovarian dysgerminoma will survive long-term. Bleomycin is an important part of ovarian germ cell tumors (OGCT) treatment, and its dose-limiting toxicity is the development of pulmonary toxicity and it is increased in patients older than 40 years. We report the case of an elderly patient with an unresectable ovarian dysgerminoma who received neoadjuvant chemotherapy and who developed fatal bleomycin pulmonary toxicity (BPT) after surgery. A monitoring of pulmonary function is not routinely recommended for detecting BPT, although together with carefully assessment for symptoms or signs suggestive of pulmonary toxicity is the best way to reduce the risk of BPT. The frequency of pulmonary events in older patients makes us to think about the possibility of either reduce the dose of bleomycin or removing it from the BEP in ovarian GCT.

show abstract

“…Because of the rarity of relapse in this population, the treatment strategies are extrapolated from clinical experience with testicular cancer. The most commonly used salvage regimens include TIP (paclitaxel, ifosfamide, cisplatin), VIP (etoposide, ifosfamide, cisplatin) or VeIP (vinblastine, ifosfamide, cisplatin) [ 8 ]. For patients with platinum-refractory disease, defined as progression within four weeks of completion of platinum-based chemotherapy, the prognosis is poor and high-dose chemotherapy with stem-cell rescue is often recommended [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Growing Teratoma Syndrome in the Setting of Sarcoidosis: A Case Report and Literature Review

et al. 2022

View full text Add to dashboard Cite

Growing teratoma syndrome (GTS) is rare and can mimic disease recurrence in patients with a history of immature teratoma. Benign hypermetabolic lymphadenopathy found on staging and surveillance computed tomography (CT) and positron emission tomography (PET) may lead to the presumption of metastatic malignancy. We report a case of a 38 year old with mixed mature and immature teratomas who developed new peritoneal masses after adjuvant chemotherapy despite a normalization of tumor markers. In addition to low FDG uptake observed in these peritoneal masses, a PET scan showed hypermetabolic lymphadenopathy and pulmonary and spleen lesions suggesting widespread metastases. Subsequent surgical resection confirmed a mixed pathology with GTS and sarcoidosis. We reviewed the current literature evidence of GTS and sarcoidosis as a benign cause of lymphadenopathy in cancer patients. We emphasize the importance of a tissue diagnosis before instituting therapy for presumed cancer recurrence to avoid potentially fatal diagnostic traps and management errors. A multiple disciplinary team approach is imperative in managing patients with suspected recurrent immature teratomas.

show abstract

Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease

Cited by 12 publications

References 24 publications

Chemotherapy for ovarian cancer during pregnancy: A systematic review and meta‐analysis of case reports and series

Chemotherapy for ovarian cancer during pregnancy: A systematic review and meta‐analysis of case reports and series

Death by bleomycin pulmonary toxicity in ovarian dysgerminoma with pathologic complete response to chemotherapy. A case report

Growing Teratoma Syndrome in the Setting of Sarcoidosis: A Case Report and Literature Review

Contact Info

Product

Resources

About